Search company, investor...

Founded Year



Corporate Majority | Acquired

Total Raised


About Sensimed

Sensimed, a Swiss medical devices company, has developed a solution to monitor fluctuations in intraocular pressure continuously up to 24 hours. The solution consists of a soft, non-invasive contact lens which encapsulates a telemetric sensor. The external system consists of an adhesive antenna worn around the eye attached to a portable recording device.

Headquarters Location

Route de Chavannes 37



+41 21 621-9191



Expert Collections containing Sensimed

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Sensimed is included in 1 Expert Collection, including Digital Health.


Digital Health

10,804 items

The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.

Sensimed Patents

Sensimed has filed 7 patents.

The 3 most popular patent topics include:

  • blindness
  • ophthalmology
  • bones of the head and neck
patents chart

Application Date

Grant Date


Related Topics




Diseases of the eye and adnexa, Blindness, Rare diseases, Ophthalmology, Syndromes


Application Date


Grant Date



Related Topics

Diseases of the eye and adnexa, Blindness, Rare diseases, Ophthalmology, Syndromes



Latest Sensimed News

Global Smart Contact Lenses Market to Witness 9.8% CAGR During 2022-2027 - Leading Players are Sensimed, Mojo Vision, Innovega, InWith, and Johnson & Johnson -

Jul 12, 2022

The Global Smart Contact Lenses Market is expected to register a CAGR of 9.8% over the forecast period, 2022-2027. The impact of COVID-19 on the smart contact lenses market's growth was adverse in the year 2020 due to fewer eye care consultations. For instance, according to data published in August 2020 by the Centers for Disease Control and Prevention and the American Academy of Ophthalmology, there was a nearly 80% initial decrease in ophthalmology visits, and as of mid-June, there was still a 40% cumulative decrease in ophthalmology visits in the United States. However, owing to the recommencement of ophthalmology practices and procedures worldwide, the market may prevail with a normal growth rate in the near future. For instance, according to the article "Tele-consultations in the wake of COVID-19 - Suggested guidelines for clinical ophthalmology," published in June 2020 in India, the Ministry of Health and Family Welfare proposed guidelines for safe ophthalmology practices in the COVID-19 scenario, such as eye care facilities should ensure that tele-counseling and teleconsultation should be encouraged to reduce patient visits and/or appointment systems can be followed to call patients needing examinations, eye investigations, or procedures. Likewise, in March 2020, the American Academy of Ophthalmology (AAO) released practice guidelines advising ophthalmologists to cease providing any treatment other than urgent and emergent care. Such factors are projected to boost the demand for smart contact lenses among the patient population, thereby leading to the growth of the market over the coming years. Furthermore, the major factors fuelling the market's growth are the rising burden of eye disorders, the growing prevalence of presbyopia in the geriatric population, the surge in advancements in glaucoma treatment technologies, and the increasing research and development activities by key market players for smart contact lens manufacturing. Smart contact lenses find their use in diagnosing diabetes and glaucoma by measuring the level of glucose in tears and monitoring intraocular pressure within the eyes. The rising burden of diabetes, leading to eye disorders, is thus expected to drive the demand for smart contact lenses, thereby significantly contributing to the market growth. For instance, as per a November 2021 published article titled, "Global Prevalence of Diabetic Retinopathy and Projection of Burden through 2045: Systematic Review and Meta-analysis", among individuals with diabetes, the global prevalence was 22.27% for diabetic retinopathy, 6.17% for vision-threatening DR (VTDR), and 4.07% for clinically significant macular edema. In addition, as per a July 2021 published article titled, "Prevalence of primary open-angle glaucoma in the last 20 years: a meta-analysis and systematic review", the study provided the most updated worldwide prevalence of primary open-angle glaucoma (POAG) for the last 20 years. As per the study results, the overall global prevalence of POAG in the population over 40 years old is 2.4%. Moreover, according to a March 2022 update, in South Korea, a POSTECH research team led by Professor Sei Kwang Hahn and Ph.D. candidate Geon-Hui Lee, in collaboration with Dr. Sangbaie Shin of PHI BIOMED Co., developed a smart contact lens-type wearable device to prevent diabetic retinopathy and treat it in its early stages by irradiating 120 W far-red/LED light to the retina. This technology for smart LED contact lenses has attracted great attention for various ophthalmologic diseases. Thus, the abovementioned factors indicate that the growing burden of eye disorders and advancements in smart contact lens technology will drive the demand for smart contact lenses over the forecast period. However, the high cost of smart contact lenses and lack of awareness pertaining to these lenses are the major factors restraining the market's growth. Key Market Trends North America Expected to Hold the Largest Share Competitive Landscape The smart contact lenses market is competitive with the presence of several global and international market players. The key players are adopting different growth strategies to enhance their market presence, such as partnerships, agreements, collaborations, new product launches, geographical expansions, mergers, and acquisitions. Some of the key players in the market are Sensimed, Mojo Vision, Innovega Inc., InWith Corporation and Johnson & Johnson among other market players. Key Topics Covered

Sensimed Frequently Asked Questions (FAQ)

  • When was Sensimed founded?

    Sensimed was founded in 2003.

  • What is Sensimed's latest funding round?

    Sensimed's latest funding round is Corporate Majority.

  • How much did Sensimed raise?

    Sensimed raised a total of $50.32M.

  • Who are the investors of Sensimed?

    Investors of Sensimed include Seed, New Value, Vertex Ventures HC, Wellington Partners, Renaissance and 6 more.

  • Who are Sensimed's competitors?

    Competitors of Sensimed include Embolx, Exogenesis, Pulsar Vascular, Avalon Laboratories, Symbios Medical Products and 7 more.


Compare Sensimed to Competitors

Belmont Instrument Logo
Belmont Instrument

Belmont Medical Technologies specializes in the development of medical devices for fluid management and critical care within the healthcare sector. The company offers a range of products including blood and fluid warming devices, temperature management systems, and hyperthermic lavage equipment designed to improve patient outcomes in various medical settings. These products are primarily utilized in areas such as anesthesia, emergency transport, intensive care, labor and delivery, military applications, surgical care, and trauma and emergency situations. It was founded in 1980 and is based in Billerica, Massachusetts.


C2C specializes in the contract manufacturing of medical devices, offering comprehensive services from product development to commercialization. The company provides expertise in design, prototyping, regulatory strategy, and pilot production, as well as manufacturing, packaging, labeling, and sterilization of medical devices. C2C primarily serves the medical device industry, catering to inventors and companies seeking to bring new products to market or scale existing ones. It is based in Melbourne, Florida.

Embolx Logo

Embolx is a medical device company that focuses on the development of microcatheters for arterial embolization procedures. The company's main products are devices that aid in the treatment of various conditions such as cancerous tumors, benign prostatic hyperplasia, and uterine fibroids by controlling blood flow and protecting non-target tissues. It was founded in 2013 and is based in Sunnyvale, California. Embolx operates as a subsidiary of Edwards Lifesciences.

NDO Surgical

Medical devices for the treatment of severe gastrointestinal disorders

EMCOOLS-Emergency Medical Cooling Systems

EMCOOLS-Emergency Medical Cooling Systems specializes in non-invasive body cooling technologies within the healthcare sector. The company offers a range of cooling products including full body suits, pads, and suits designed for targeted temperature management, heat stroke treatment, cryotherapy, and personal cooling. These products are utilized by various sectors including hospitals, emergency medical services, and hazardous materials personnel. It is based in Austria.

SpineAlign Medical

SpineAlign Medical is an early-stage medical device company focused on developing minimally-invasive products for spine disorders. The company's main product is a nitinol implant designed to treat vertebral compression fractures, primarily affecting osteoporosis patients. SpineAlign Medical's technologies cater to the healthcare sector, with a focus on improving patient outcomes in spinal treatments. It is based in Pleasanton, California.


CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.